Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dimethyl glutamate

Biogen Idec building

Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease

The drug failed to meet the primary efficacy endpoint in a phase 2 study

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

- PMLiVE

Biogen reports new data backing long-term benefit of Spinraza

Company also revealed new analysis suggesting benefits associated with a higher therapy dose

Biogen Idec building

Biogen to begin shipping newly approved Alzheimer’s treatment in two weeks

Just days after the drug was approved by the FDA advisory panel, two of its members have resigned

- PMLiVE

FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision

FDA is requiring Biogen to conduct a new randomised, controlled clinical trial to verify the drug’s clinical benefit for Alzheimer’s patients

- PMLiVE

Piloting a route to the biosimilars opportunities in Europe

Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy

Biogen Idec building

Biogen and Envisagenics to advance RNA splicing research for CNS diseases

Envisagenics’ SpliceCore platform can be used to identify, test and validate RNA splicing errors at scale

- PMLiVE

Biogen and Capsigen to collaborate on gene therapies

Biogen will gain exclusive right for undisclosed number of CNS and neuromuscular disease targets

Biogen Idec building

Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’

Move comes after mounting pressure from patients and campaigners

Biogen Idec building

Biogen reveals new data for MS therapies Tysabri and Vumerity

New data comes ahead of FDA decision on company's controversial Alzheimer’s drug aducanumab

Roche Basel Switzerland

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The data was presented virtually at the American Academy of Neurology annual meeting

Novartis day

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

New post hoc data comes from phase 3 ASCLEPIOS trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links